Therapeutic Drug Monitoring of Aminoglycosides in Veterinary Patients: Indications and Protocols

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Therapeutic Drug Monitoring (TDM) of aminoglycosides is indicated for veterinary patients with pre-existing renal disease, the elderly, obese individuals, those receiving concurrent nephrotoxins, or those failing to respond to empiric therapy, due to their narrow therapeutic index and concentration-dependent toxicity.
• Peak serum concentrations should ideally be 8-10 times the pathogen's Minimum Inhibitory Concentration (MIC), commonly targeted at 20-40 mg/L for gentamicin and amikacin, with trough concentrations kept below 2 mg/L (gentamicin) and 5 mg/L (amikacin) to minimize nephrotoxicity.
• For once-daily aminoglycoside dosing, the target peak concentration remains 8-10 times the MIC, but trough concentrations should ideally be undetectable to leverage the post-antibiotic effect and reduce toxicity.
• Peak serum samples are collected 30-60 minutes post-intravenous infusion or 60 minutes post-intramuscular administration, while trough samples are drawn within 30 minutes prior to the next scheduled dose.
• Therapy duration exceeding 9-10 days significantly increases the risk of nephrotoxicity and ototoxicity, necessitating intensified monitoring and careful reassessment of the need for continued treatment.
• Automated fluorescence polarization immunoassays are the most practical method for serum aminoglycoside measurement in clinical settings, offering rapid, specific results, though awareness of potential cross-reactivity is important.

Aminoglycosides remain indispensable for treating serious aerobic gram-negative infections in veterinary patients despite their narrow therapeutic index. Their concentration-dependent bactericidal activity, prolonged post-antibiotic effect, and predictable toxicity profile make them well suited to therapeutic drug monitoring (TDM), yet the practical application of TDM in clinical practice varies widely across species and practice settings. This article provides a monitoring protocol for the practicing veterinarian, covering when to measure serum drug concentrations, how to time those measurements, which target values to apply, and how to use the results to adjust therapy and prevent nephrotoxicity and ototoxicity.

The reader is assumed to be familiar with aminoglycoside pharmacology and basic pharmacokinetic principles. The focus here is procedural: translating published pharmacokinetic data and toxicity research into a defensible monitoring framework for dogs, cats, horses, food animals, and exotic species. Where the evidence base is thin or contested, that uncertainty is stated directly. Current formulary and label references must be consulted for specific doses, as approved regimens vary by species, indication, and jurisdiction.

At a Glance

Pharmacologic Basis for Monitoring

Aminoglycosides exhibit concentration-dependent killing, meaning that the rate and extent of bacterial eradication increase with rising drug concentration above the MIC. The pharmacodynamic index that best predicts clinical efficacy is the ratio of peak concentration to MIC, with a ratio of 8 to 10 associated with improved outcomes. This relationship was established in human clinical studies and has been applied to veterinary dosing strategies, including the design of amikacin regimens in marine mammals where allometric scaling was used to target peak concentrations 8 to 10 times the expected pathogen MIC.

The same concentration-dependent behavior underlies the toxicity profile. Aminoglycosides are taken up into renal tubular epithelial cells and cochlear and vestibular hair cells by active transport, a process that saturates at high concentrations. This explains why a single large daily dose can be less nephrotoxic than multiple smaller doses: the saturable uptake mechanism is overwhelmed and the drug is cleared before intracellular accumulation becomes damaging. The post-antibiotic effect, lasting several hours, permits the drug-free interval that makes once-daily dosing feasible.

Adaptive resistance further supports extended-interval dosing. After initial exposure, bacterial uptake of the drug decreases for a period of hours, creating a window during which additional doses add little killing but continue to drive host toxicity. A long dosing interval allows this adaptive resistance to reverse before the next dose.

Toxicity Mechanisms and Risk Factors

Nephrotoxicity is the most clinically significant adverse effect in veterinary patients. The drug accumulates in the proximal tubular epithelium, where it interferes with phospholipid metabolism and mitochondrial function, leading to tubular necrosis. Risk factors identified from human clinical experience and animal models include preexisting renal disease, advanced age, obesity, volume depletion, hypokalemia, and concurrent use of other nephrotoxic drugs such as nonsteroidal anti-inflammatory agents, loop diuretics, and amphotericin B. These same risk factors are clinically relevant in veterinary patients, although species-specific data are limited.

Ototoxicity, affecting both cochlear and vestibular function, is less readily detected in animals and may go unrecognized until significant hearing or balance loss has occurred. Neuromuscular blockade is rare but can be life-threatening, particularly with rapid intravenous administration or concurrent use of neuromuscular blocking agents.

The duration of therapy is an independent risk factor. Keeping treatment to 9 to 10 days or less, in a well-hydrated, normokalemic patient, minimizes the cumulative drug exposure that drives toxicity. When longer courses are unavoidable, TDM becomes correspondingly more important.

Analytical Methods for Serum Drug Measurement

Reliable TDM depends on accurate assay methodology. Aminoglycosides lack a chromophore, are highly polar, and do not volatilize, all of which complicate chemical analysis. Microbiological assays are inexpensive but lack precision and specificity, and they are affected by concurrently administered antimicrobials. Immunoassays, particularly automated fluorescence polarization immunoassays, are the most practical option for serum drug measurement in clinical settings because they are rapid, specific, and require minimal sample preparation.

Chromatographic methods, including high-performance liquid chromatography and gas chromatography, offer greater accuracy and the ability to measure multiple analytes simultaneously, but they require derivatization and are generally reserved for reference laboratories and research applications. For clinical decision-making, the practicing veterinarian should use a laboratory that participates in external quality assurance and should be aware of the assay type used, as immunoassay cross-reactivity and calibration differences can affect reported values.

Indications for Therapeutic Drug Monitoring

TDM is not required for every aminoglycoside course. Short courses in young, healthy animals with normal renal function and a documented susceptible pathogen rarely justify the cost and logistical burden. Monitoring is indicated when the consequences of treatment failure or toxicity are severe, or when the patient's physiology makes standard dosing unpredictable.

Specific indications include preexisting renal disease or azotemia, advanced age, obesity, concurrent nephrotoxin administration, failure to respond to empiric therapy, and the need for treatment beyond 9 to 10 days. Critically ill patients with dynamic fluid balance, sepsis, or altered cardiac output also warrant monitoring because their volume of distribution and clearance may change rapidly during treatment. In food animals, TDM is rarely performed due to cost and the lack of approved monitoring infrastructure, but the same pharmacokinetic principles apply and withdrawal intervals must be respected.

Sampling Strategy and Timing

The timing of blood collection determines which pharmacokinetic parameter is being assessed and therefore what clinical question can be answered. For aminoglycosides, two samples are usually required: a peak sample and a trough sample. The peak sample should be collected 30 to 60 minutes after intravenous administration and 60 to 90 minutes after intramuscular administration. This timing captures the distribution phase and reflects the maximum serum concentration achieved after the dose has equilibrated. The trough sample is collected immediately before the next dose, at the end of the dosing interval.

For once-daily regimens, the trough sample is drawn at 24 hours after administration. For traditional multiple-daily dosing, the trough is drawn at 8 or 12 hours depending on the interval. The peak concentration is the primary pharmacodynamic driver of efficacy, as aminoglycosides exhibit concentration-dependent killing. The ratio of peak concentration to minimum inhibitory concentration (MIC) is the best predictor of clinical response, with a target ratio of 8 to 10:1 commonly cited in the literature. The trough concentration is the primary safety parameter, as persistent elevation above the toxic threshold indicates drug accumulation and predicts nephrotoxicity.

A single trough sample can be used to estimate the elimination half-life if the patient has received at least two doses and the dosing interval is known. Two trough samples collected 12 to 24 hours apart allow calculation of the elimination rate constant and clearance. This approach is useful in patients with suspected renal impairment or in those whose clinical status is changing rapidly.

Target Concentrations and Interpretation

Target serum concentrations differ between traditional multiple-daily dosing and once-daily regimens. The table below summarizes commonly used targets for gentamicin and amikacin in dogs and cats. These values are derived from clinical experience and pharmacokinetic studies, and current formulary references should be consulted before applying them to individual patients.

A peak concentration below the target range suggests underdosing or an increased volume of distribution. This occurs in patients with sepsis, burns, ascites, or third-space fluid losses, where the extracellular fluid volume is expanded. A peak concentration above the target range is less common but may occur in dehydrated patients or those with reduced cardiac output. A trough concentration above the target range indicates drug accumulation and mandates dose interval extension or dose reduction.

The interpretation of a single set of peak and trough concentrations requires knowledge of the patient's renal function. Serum creatinine and urea nitrogen should be measured at baseline and repeated daily during therapy. A rising creatinine of 0.5 mg/dL or more above baseline, or an increase of 50 percent, should trigger immediate reassessment of the dosing regimen and consideration of drug discontinuation. The FDA Center for Veterinary Medicine provides regulatory context on approved drug use and adverse event reporting that informs clinical decision-making.

Dose Adjustment Protocols

When a measured concentration falls outside the target range, the dose is adjusted using standard pharmacokinetic principles. For a low peak concentration, the dose is increased proportionally. If the measured peak is 15 mg/L and the target is 30 mg/L, the dose is doubled. For a high trough concentration, the dosing interval is extended instead of the dose reduced. This preserves the peak concentration needed for efficacy while allowing more time for drug elimination.

A practical approach is to calculate the patient's elimination half-life from two trough concentrations using the formula t1/2 = 0.693 / ke, where ke is the elimination rate constant derived from the slope of the log-linear concentration decline. The dosing interval should be approximately three to four half-lives. In a patient with normal renal function, gentamicin and amikacin have half-lives of 2 to 3 hours in dogs, so an 8-hour interval is appropriate. In a patient with a measured half-life of 6 hours, the interval should be extended to 24 hours.

For patients with preexisting renal disease, the elderly, and those receiving concurrent nephrotoxins, more conservative targets and more frequent monitoring are warranted. The risk factors for aminoglycoside toxicity are well established and include duration of therapy beyond 9 to 10 days, hypokalemia, dehydration, and concurrent use of other nephrotoxic drugs. These factors should be assessed before therapy begins and reassessed daily. The MSD Veterinary Manual provides species-specific pharmacology and dosing guidance that should be consulted alongside any monitoring protocol.

Monitoring Schedule and Documentation

The monitoring schedule depends on the duration of therapy and the patient's risk profile. For a planned course of 3 to 5 days in a patient with normal renal function, a single peak and trough measurement after the second or third dose is usually sufficient. For therapy extending beyond 5 days, or in patients with renal impairment, monitoring should be repeated every 2 to 3 days. Daily monitoring is reserved for critically ill patients with unstable renal function or those receiving concurrent nephrotoxins.

Each monitoring event should be documented with the following elements: the drug and dose administered, the route and time of administration, the exact time of blood collection for both peak and trough samples, the measured concentrations, the laboratory reference range, the patient's current body weight, serum creatinine, urine output if available, and any clinical signs of toxicity. Serial measurements of the same parameters allow trend analysis, which is more informative than a single time point.

The laboratory method used for measurement should be recorded, as chromatographic methods for analysis of aminoglycoside antibiotics and immunoassays can yield different results. Immunoassays are the most common method in commercial laboratories and are appropriate for clinical monitoring, but they may cross-react with metabolites or other compounds. High-performance liquid chromatography offers greater specificity but is less widely available and more labor-intensive. The current methodologies for the analysis of aminoglycosides review describes the relative strengths and limitations of each approach.

Species-Specific Considerations

The pharmacokinetics of aminoglycosides vary across species, and dosing and monitoring protocols must be adapted accordingly. In large animals, the volume of distribution and clearance differ from small animals, and allometric scaling may be used to estimate initial doses. A study of amikacin in a killer whale and a beluga whale demonstrated that allometric relationships derived from mature animals can predict the volume of distribution and guide initial dosing, with subsequent therapeutic drug monitoring used to refine the regimen. This approach is applicable to exotic and zoo species where pharmacokinetic data are limited.

In food animals, the primary concern is tissue residues and withdrawal times. Aminoglycosides are not approved for use in many food-producing species, and extralabel use carries substantial regulatory risk. The WOAH terrestrial animal health standards address residue monitoring and trade-related requirements that must be considered before initiating therapy. Therapeutic drug monitoring in food animals is rarely performed because of cost and logistical constraints, but it may be justified in valuable breeding stock or when renal function is compromised.

In neonatal animals, the elimination half-life is prolonged because of immature renal function, and dosing intervals must be extended accordingly. The clinical pharmacokinetics of isepamicin, an aminoglycoside similar to amikacin, illustrate the reduced clearance observed in neonates and the need for once-daily dosing in this population. Similar principles apply to gentamicin and amikacin in veterinary neonates.

When Monitoring Is Not Required

Therapeutic drug monitoring is not indicated for short courses of therapy lasting 24 to 48 hours in patients with normal renal function and no concurrent risk factors. It is also not indicated when the infection is localized and systemic absorption is minimal, such as with topical otic or ophthalmic preparations. In these situations, the cost and logistical burden of monitoring outweigh the clinical benefit.

Monitoring is also of limited value when the laboratory turnaround time exceeds the dosing interval. If results are not available before the next dose is due, the information cannot guide real-time adjustment. In such cases, clinicians should rely on clinical assessment, serial renal function testing, and conservative dosing strategies. The AVMA antimicrobial stewardship resources emphasize that judicious use of aminoglycosides, including limiting duration and avoiding unnecessary exposure, is the most effective strategy for preventing toxicity.

Recognized Complications and Early Detection

Nephrotoxicity remains the most frequently encountered complication of aminoglycoside therapy. It typically presents as a nonoliguric rise in serum creatinine concentration after five to seven days of treatment. Early detection requires baseline creatinine measurement before initiation, followed by reassessment every 48 to 72 hours during therapy. A rise of more than 0.5 mg/dL from baseline, or a 50 percent increase, warrants immediate dose interval extension and re-evaluation of the indication for continued treatment. Urinary enzyme assays, such as measurement of gamma-glutamyl transferase or N-acetyl-beta-D-glucosaminidase, can detect tubular injury earlier than serum creatinine, but their clinical availability is limited and their predictive value for irreversible injury remains debated.

Ototoxicity is less readily detected in veterinary patients. Cochlear damage presents as progressive hearing loss that owners may not recognize until it is advanced. Vestibular toxicity manifests as head tilt, ataxia, or nystagmus. No reliable serum concentration threshold predicts ototoxicity, and monitoring relies on clinical vigilance and limiting treatment duration. The risk of both nephrotoxicity and ototoxicity increases with treatment exceeding nine to ten days, concurrent use of other nephrotoxins, preexisting renal disease, and electrolyte disturbances such as hypokalemia or hypomagnesemia Whelton, therapeutic initiatives for the avoidance of aminoglycoside toxicity.

Neuromuscular blockade is a rare but potentially fatal complication. It occurs most often with rapid intravenous administration, concurrent use of neuromuscular blocking agents, or in patients with myasthenia gravis. Detection relies on recognizing progressive weakness or respiratory compromise during or shortly after drug administration. Immediate discontinuation and calcium administration are indicated when this complication is suspected.

Common Errors and Corrective Actions

The most frequent error in aminoglycoside monitoring is sampling at the wrong time. Trough samples drawn too early after dose administration overestimate the true trough and may lead to inappropriate dose interval extension. Peak samples drawn after the distribution phase has not completed underestimate the true peak. Sampling times must be recorded precisely, and the laboratory should be informed of the actual collection time relative to drug administration.

A second common error is failure to adjust the monitoring plan when renal function changes during therapy. A patient with normal baseline renal function can develop acute kidney injury from sepsis, hypotension, or concurrent drugs, and the aminoglycoside elimination half-life will lengthen accordingly. Serial creatinine measurement is not optional in patients receiving more than three days of therapy.

A third error is interpreting a single concentration in isolation. Aminoglycoside pharmacokinetics vary substantially between individuals, and a single measurement cannot distinguish between a patient with a small volume of distribution and rapid clearance from one with a large volume of distribution and slow clearance. At least one peak and one trough measurement are required to make a rational dose adjustment KuKanich et al., comparison of amikacin pharmacokinetics in a killer whale and a beluga whale.

Limitations of the Evidence and Areas of Expert Disagreement

The evidence base for aminoglycoside therapeutic drug monitoring in veterinary medicine is thin. Most pharmacokinetic principles are extrapolated from human medicine, where once-daily dosing has become standard because it exploits concentration-dependent killing and the post-antibiotic effect while reducing accumulation in the renal cortex Tod et al., clinical pharmacokinetics and pharmacodynamics of isepamicin. Whether these benefits translate equally across all veterinary species is not established.

Expert opinion differs on the value of routine peak concentration monitoring. Some authorities argue that for once-daily dosing regimens, only trough concentrations need to be measured, because the peak is predictably high when the dose is calculated on body weight. Others maintain that peak measurement is essential to confirm that the concentration exceeds eight to ten times the minimum inhibitory concentration of the pathogen, particularly in critically ill patients with altered volume of distribution. The latter position is supported by pharmacokinetic studies in marine mammals, where allometric scaling was required to achieve target peak concentrations KuKanich et al., comparison of amikacin pharmacokinetics.

The optimal target trough concentration also remains contested. Traditional targets of less than 2 mg/L for gentamicin and less than 5 mg/L for amikacin were derived from older, multiple-daily dosing regimens. Whether these thresholds apply to once-daily dosing, where the trough is measured 24 hours after administration, is uncertain. Some clinicians accept higher trough concentrations with once-daily dosing because the longer interval provides a drug-free period that allows adaptive resistance to reverse.

Referral, Consultation, and Regulatory Reporting

Referral to a veterinary clinical pharmacologist or a specialist in internal medicine is warranted when dose adjustment fails to achieve target concentrations, when renal function deteriorates despite appropriate monitoring, or when the patient requires more than seven days of therapy. A specialist can perform formal pharmacokinetic analysis and design an individualised dosing regimen.

Laboratory consultation is appropriate when assay results seem inconsistent with the clinical picture. Immunoassays may cross-react with other compounds, and chromatographic methods require derivatization that can introduce variability Isoherranen and Soback, chromatographic methods for analysis of aminoglycoside antibiotics. The laboratory should be asked to confirm unusual results before a dose change is made on the basis of a single measurement.

Regulatory reporting obligations arise when an adverse drug event occurs in a patient treated with an approved animal drug. The FDA Center for Veterinary Medicine maintains an adverse event reporting system for animal drugs, and veterinarians in the United States are encouraged to report suspected adverse reactions FDA Center for Veterinary Medicine animal drug information. Reporting requirements differ outside the United States, and veterinarians should consult their national regulatory authority. Antimicrobial stewardship principles also support documenting the indication, dose, and monitoring plan for every aminoglycoside course, so that prolonged or repeated use can be reviewed critically AVMA antimicrobial use and stewardship resources.

Frequently Asked Questions

How Should I Proceed When In-House Assays Are Unavailable?

When immunoassay platforms are not accessible, submit serum samples to a commercial veterinary diagnostic laboratory that offers validated aminoglycoside assays. Collect the sample at the designated time, separate serum promptly, and ship according to the laboratory's stability requirements. Microbiological assays remain a semi-quantitative alternative, but they are less precise and may be affected by concurrent antimicrobial therapy. High-performance liquid chromatography offers accurate measurement but is rarely practical for routine clinical monitoring. If laboratory access is delayed, continue therapy using published population-based dosing guidelines and monitor renal function closely, as chromatographic methods for aminoglycoside analysis are not universally available in practice settings.

What Is the Minimum Monitoring Protocol for a Short Course of Gentamicin?

For a three to five day course in a young, previously healthy patient with normal renal function, measure a trough concentration before the second or third dose and check serum creatinine at baseline and at the end of therapy. A peak concentration adds value when the infection is severe, the pathogen susceptibility is uncertain, or the patient is obese, since volume of distribution varies with body composition. The clinical toxicity of aminoglycosides can be minimized by appropriate dosing for periods not exceeding nine to ten days in well-hydrated patients, so short courses with basic monitoring are acceptable. Extend the protocol if the patient develops azotemia, requires concurrent nephrotoxins, or fails to respond clinically.

How Do I Interpret Aminoglycoside Levels in a Patient with Acute Kidney Injury?

Acute kidney injury prolongs the elimination half-life and raises trough concentrations, which increases the risk of further nephrotoxicity. Hold the next dose and repeat the serum concentration after 24 hours to estimate the new elimination rate. If the trough remains elevated, extend the dosing interval instead of reducing the dose, since aminoglycoside efficacy depends on achieving high peak concentrations. Consult a veterinary clinical pharmacologist or nephrologist for complex cases. The pharmacokinetic and pharmacodynamic properties of aminoglycosides, including concentration-dependent killing and renal elimination, support interval extension as the primary adjustment in renal impairment. Recheck creatinine daily until values stabilize, and consider alternative antimicrobials if renal function does not improve.

Can Therapeutic Drug Monitoring Be Justified Economically in Small Animal Practice?

The cost of two or three serum assays often exceeds the cost of the drug itself, but the expense is justified when the infection is life-threatening, the patient has preexisting renal disease, or treatment will exceed five days. Monitoring prevents prolonged hospitalization from nephrotoxicity and reduces the risk of therapeutic failure from subtherapeutic peaks. For routine perioperative prophylaxis or uncomplicated urinary tract infections, monitoring is not cost-effective. Discuss the expected benefits with the owner before initiating therapy, and document the rationale in the medical record. Automated immunoassays are the most appropriate methods for serum aminoglycoside measurement, and their cost should be weighed against the consequences of unmonitored therapy in high-risk patients.

What Records Should I Keep for Aminoglycoside Monitoring and Stewardship?

Record the indication for therapy, the dose and route, the exact time of drug administration, the time of each blood sample, the assay result, and the subsequent dose adjustment. Include baseline and serial serum creatinine values, urine output estimates, and any clinical signs of ototoxicity or vestibular dysfunction. Document the planned duration of therapy and the criteria for stopping. These records support antimicrobial stewardship reviews and are essential if adverse effects occur. Professional guidance on judicious antimicrobial use and stewardship principles emphasizes documentation as a core component of responsible prescribing. In food animals, additional records may be required for withdrawal period verification, and regulatory information on approved animal drugs and extralabel use should be consulted.

How Should I Explain Monitoring Recommendations to a Client Who Is Reluctant?

Explain that the blood tests measure whether the antibiotic concentration is high enough to kill the bacteria but low enough to protect the kidneys. Frame the tests as a safety check, not an optional extra. State that the alternative is treating without knowing the drug levels, which carries a higher risk of kidney damage or treatment failure. Provide a simple estimate of the additional cost and the number of samples required. If the client declines, document the refusal and proceed with a conservative dosing protocol, checking renal values more frequently. The MSD Veterinary Manual provides species-specific pharmacology background that can support client education materials, though the conversation itself should remain practical and focused on the individual patient's risk profile.

Related Clinical & Scientific Guides

• Veterinary Formulary Essentials: Navigating Drug References
• Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy
• Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review

References and Further Reading

• Chromatographic methods for analysis of aminoglycoside antibiotics.. 1999.
• Therapeutic initiatives for the avoidance of aminoglycoside toxicity.. 1985.
• Current methodologies for the analysis of aminoglycosides.. 2000.
• Clinical pharmacokinetics and pharmacodynamics of isepamicin.. 2000.
• Comparison of amikacin pharmacokinetics in a killer whale (Orcinus orca) and a beluga whale (Delphinapterus leucas).. 2004.
• A Novel Simultaneous Reverse Phase High Performance Liquid Chromatography (RP-HPLC) Method for The Determination of Gentamicin and Amoxicillin in Milk Samples. 2026.
• FDA Center for Veterinary Medicine: Animal Drug Information. FDA CVM.
• AVMA Antimicrobial Use and Stewardship. American Veterinary Medical Association.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.

Related Articles

• Therapeutic Drug Monitoring of Cyclosporine in Veterinary Dermatology: Indications and Interpretation
• Therapeutic Drug Monitoring in Veterinary Practice: Indications and Interpretation
• Therapeutic Drug Monitoring of Digoxin in Canine Cardiac Disease: Indications and Interpretation
• Therapeutic Drug Monitoring in Epileptic Dogs: Antiepileptic Drug Levels
• Drug Interactions with Antihypertensive Medications in Veterinary Patients

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.